Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
HR+
How would you approach a premenopausal woman with HR+, HER2- metastatic breast and a PIK3CA mutation?
Answer from: Medical Oncologist at Community Practice
Ovarian ablation of some sort + AI + CDK 4/6 inhibitor. At relapse, consider fulvestrant + alpelisib.
Sign in or Register to read more
7041
Related Questions
Is there any benefit of anastrozole in addition to fulvestrant and palbociclib in a patient with HR+ metastatic breast cancer?
Would you give adjuvant Tamoxifen to a premenopausal with ER+/PR+/Her2- Stage IA [pT1a, pN0(I+1)] breast cancer s/p bilateral mastectomies?
With the recent FDA approval of adjuvant ribociclib, how are you deciding between ribociclib and abemaciclib for high risk HR+/HER2− early breast cancer?
When do you recommend preoperative chemotherapy or hormonal therapy for ER+ breast cancer?
What are your top takeaways in Breast Cancer from ESMO 2024?
Would you offer local therapy with either SBRT or Y-90 in a patient with metastatic ER+ HER2 low breast cancer with two oligometastatic liver lesions currently on AI + CDK4/6 inhibitor?
Would you recommend adjuvant endocrine therapy in combination with immunotherapy for triple negative metaplastic breast cancer with residual disease that is ER strongly positive?
How would you decide the duration of ovarian suppression in premenopausal females with early stage ER+ breast cancer?
What are your top takeaways in Medical Oncology from SABCS 2024?
Does the degree of hormone receptor positivity influence your decision to perform Oncotype testing?